Yüksel Ürün, Professor of Medical Oncology at Ankara University, shared Amol Akhade’s, Senior Consultant at Fortis Hospitals Mumbaion, post X, adding:
“These HARMONi OS curves matter. Geographic consistency is now reassuring.
Updated OS: HR 0.76 overall, with the same HR in Western patients.
Stronger totality of evidence. FDA approval just became more plausible?”
Quoting Amol Akhade’s post:
“These OS curves look much better ( than THE other Harmoni trial ).”
You can also read:
